The results could sway U.S. regulators to convert Braftovi’s accelerated clearance in colorectal tumors into a full approval ...

Medicare will soon negotiate prices for 15 more drugs as part of an effort to reduce costs for older adults and people with disabilities.

The firm will share new overall survival data from the INAVO120 trial with regulators to support the breast cancer drug's approval.

Among patients with advanced PIK3CA-mutated, HR-positive/HER2-negative breast cancer, Itovebi-based treatment generated positive overall survival results.

Levi Garraway, Roche’s chief medical officer and head of global product development, said: “The INAVO120 overall survival ...

Democrats sought answers from RFK Jr. on how the Trump administration would handle Medicare price negotiations after a short ...

The U.S. Centers for Medicare & Medicaid Services, or CMS, said it is considering ways to bring "greater transparency" to the Medicare drug pricing negotiation program mandated under the Inflation ...

The U.S. government said on Wednesday it will aim for "greater transparency" in Medicare drug price negotiations under ...

The US government said on Wednesday it will aim for "greater transparency" in Medicare drug price negotiations under ...

The U.S. Centers for Medicare and Medicaid Services (CMS) said on Wednesday that it would seek “greater transparency” in drug ...

Roche’s freshly approved PI3K inhibitor Itovebi can help extend the lives of certain patients with breast cancer when used in ...

Financial analysis of Pfizer Inc. stock ahead of its earnings release. PFE faces significant headwinds from patent expiries, click for my updated look at the stock.